Insights On Drug Development
-
Calcium Carbonate Vs Titanium Dioxide: Why Particle Engineering Matter
11/10/2025
Discover how particle-engineered calcium carbonate offers a viable alternative to titanium dioxide in tablet coatings, achieving good opacity, process efficiency, and comparable tablet properties.
-
Calcium Carbonate As TiO2 Alternative In Coating
11/7/2025
Explore how calcium carbonate can replace titanium dioxide in tablet coating, as well as learn formulation strategies and review color performance data to support high-quality finishes in applications.
-
Does A One-Site CDMO Make A Difference In Drug Development?
11/7/2025
A one-site CDMO streamlines drug development by co-locating R&D, GMP, and manufacturing. This integration accelerates tech transfer and decision-making, significantly compressing project timelines.
-
API In Capsule Vs. The Lost Art Of Formulation Development
11/5/2025
API-in-capsule offers a fast path for early clinical data, but it can't eliminate the need for full formulation development. Weighing the potential for higher total development time and cost is critical.
-
AI Based Screening And Selection Of Co-Formers For Co-Crystallization
11/4/2025
Explore how AI and quantum chemistry are accelerating co-crystal screening and solving solubility challenges in drug development, as well as key technical considerations for identifying optimal co-formers.
-
Smarter CMC Strategies To Accelerate Next-Gen Biologics To The Clinic
10/23/2025
Learn how process design and cross-functional collaboration mitigate risks and accelerate the path from early development to FIH manufacturing through real-world case studies of practical approaches.
-
How Lipid Nanoparticles Enable Next-Gen Delivery
10/20/2025
Cell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.
-
Spray Dried Dispersions In Controlled Release Formulations
10/16/2025
Integrating spray dried dispersions with CR strategies addresses poor drug solubility and the need for tailored release kinetics. Explore considerations to ensure stability and sustained supersaturation.
-
From First-In-Human To Proof-Of-Concept — Quicker, Smarter, Streamlined
10/14/2025
Explore examples of smarter SAD/MAD trial designs including multi-part and hybrid protocols, regulatory foresight, recruitment considerations, and operational strategies that keep programs moving.
-
Top 8 Considerations For Choosing A PDX Model
10/7/2025
To guide your decision-making, we’ve outlined the top 10 criteria to consider when evaluating PDX models for your next oncology research or drug development program.